X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
female (9) 9
humans (9) 9
middle aged (8) 8
cancer (7) 7
oncology (7) 7
aged (6) 6
breast cancer (6) 6
care and treatment (6) 6
analysis (5) 5
male (5) 5
adult (4) 4
neoplasm staging (4) 4
prognosis (4) 4
salivary gland neoplasms - genetics (4) 4
survival (4) 4
aged, 80 and over (3) 3
breast neoplasms - drug therapy (3) 3
breast-cancer (3) 3
chemotherapy (3) 3
egfr (3) 3
immunohistochemistry (3) 3
in situ hybridization, fluorescence (3) 3
kaplan-meier estimate (3) 3
medicine & public health (3) 3
obstetrics & gynecology (3) 3
oncology, experimental (3) 3
pathology (3) 3
poor-prognosis (3) 3
research (3) 3
salivary gland cancer (3) 3
salivary gland neoplasms - metabolism (3) 3
salivary gland neoplasms - pathology (3) 3
surgery (3) 3
adenoid cystic carcinoma (2) 2
advanced breast cancer (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
biomarkers, tumor - analysis (2) 2
biomarkers, tumor - genetics (2) 2
breast neoplasms - pathology (2) 2
c-met (2) 2
cancer patients (2) 2
cancer research (2) 2
carcinoma - genetics (2) 2
carcinoma - metabolism (2) 2
carcinoma - pathology (2) 2
cell cycle (2) 2
confidence intervals (2) 2
dentistry (2) 2
dentistry, oral surgery & medicine (2) 2
disease-free survival (2) 2
further section (2) 2
gene amplification (2) 2
gene copy number (2) 2
germany (2) 2
head and neck cancer (2) 2
her2 (2) 2
her2-positive (2) 2
in-situ hybridization (2) 2
met (2) 2
metastasis (2) 2
mucoepidermoid carcinoma (2) 2
multivariate analysis (2) 2
palbociclib (2) 2
parotid-gland (2) 2
patient outcomes (2) 2
plus (2) 2
prognostic-factors (2) 2
proportional hazards models (2) 2
prospective studies (2) 2
proto-oncogene proteins c-met - genetics (2) 2
pten (2) 2
pten phosphohydrolase - genetics (2) 2
quality of life (2) 2
radiotherapy (2) 2
receptor, epidermal growth factor - genetics (2) 2
receptor, erbb-2 - analysis (2) 2
receptor, erbb-2 - genetics (2) 2
retrospective studies (2) 2
risk factors (2) 2
salivary gland neoplasms - mortality (2) 2
surveys and questionnaires (2) 2
survival analysis (2) 2
survivin (2) 2
time factors (2) 2
treatment outcome (2) 2
women (2) 2
19 (1) 1
1st-line therapy (1) 1
abc4 (1) 1
acquired-resistance (1) 1
adenocarcinoma - diagnosis (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - metabolism (1) 1
adenocarcinoma - mortality (1) 1
adjuvant treatment (1) 1
administration, oral (1) 1
adolescent (1) 1
adults (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer
Journal Article
Human Pathology, ISSN 0046-8177, 2012, Volume 43, Issue 6, pp. 921 - 931
Summary Increased gene copy number (high polysomy or amplification) of EGFR and HER2 has evolved as a predictor for response to targeted therapy. STAT3 and the... 
Pathology | pSTAT3 | Prognosis | Survivin | HER2 | Salivary gland cancer | EGFR | IN-SITU HYBRIDIZATION | CYTOPLASMIC EXPRESSION | PATHOLOGY | BREAST-CANCER | POOR-PROGNOSIS | COLORECTAL-CANCER | EPIDERMAL-GROWTH-FACTOR | ADENOID CYSTIC CARCINOMA | SQUAMOUS-CELL CARCINOMAS | GENE COPY NUMBER | FACTOR RECEPTOR GENE | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Inhibitor of Apoptosis Proteins - genetics | Salivary Gland Neoplasms - genetics | Tissue Array Analysis | Humans | Male | Salivary Gland Neoplasms - metabolism | Female | Carcinoma - pathology | Inhibitor of Apoptosis Proteins - analysis | STAT3 Transcription Factor - genetics | Inhibitor of Apoptosis Proteins - biosynthesis | Receptor, Epidermal Growth Factor - biosynthesis | Receptor, ErbB-2 - biosynthesis | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Proportional Hazards Models | In Situ Hybridization, Fluorescence | STAT3 Transcription Factor - analysis | Gene Dosage | Receptor, Epidermal Growth Factor - analysis | STAT3 Transcription Factor - biosynthesis | Genes, erbB-1 | Genes, erbB-2 | Carcinoma - genetics | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Receptor, ErbB-2 - analysis | Neoplasm Staging | Salivary Gland Neoplasms - pathology | Immunohistochemistry | Genes | Tumors | Cancer | Confidence intervals | Gene amplification | Lung cancer | Cell cycle | Breast cancer | Histology | Kinases | Multivariate analysis | Microwave heating | Apoptosis
Journal Article
Journal of Cranio-Maxillo-Facial Surgery, ISSN 1010-5182, 2016, Volume 44, Issue 9, pp. 1453 - 1462
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 766 - 773
Background: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results... 
paclitaxel | first line | pertuzumab | dual HER2 blockade | HER2-positive | metastatic breast cancer | WEEKLY PACLITAXEL | ONCOLOGY | NAB-PACLITAXEL | PROGRESSION-FREE SURVIVAL | DOCETAXEL
Journal Article
Journal Article
Breast Care, ISSN 1661-3791, 03/2018, Volume 13, Issue 1, pp. 48 - 58
The Advanced Breast Cancer Fourth Consensus (ABC4) on diagnosis and treatment of advanced breast cancer (ABC) again took place in Lisbon, on November 2-4,... 
Consensus | Brain metastases | Advanced breast cancer | ABC4 | Personalized medicine | BRCA-Associated | HR-positive/HER2-positive | BRCA-associated | ADVANCED BREAST-CANCER | GUIDELINES | AGO RECOMMENDATIONS | OBSTETRICS & GYNECOLOGY | PALBOCICLIB | ONCOLOGY | FULVESTRANT | DOUBLE-BLIND | PHASE-3 TRIAL | UPDATE 2017 | 1ST-LINE THERAPY | HER2-positive | HR-positive
Journal Article
Head & Neck, ISSN 1043-3074, 04/2014, Volume 36, Issue 4, pp. 517 - 523
Journal Article
Journal Article
Journal Article
Journal Article
Breast Care, ISSN 1661-3791, 03/2018, Volume 13, Issue 1, pp. 1 - 4
Journal Article